What are the chances of Apellis Pharmaceuticals Inc (APLS) Stock turning the corner?

Jefferies raised the price target for the Apellis Pharmaceuticals Inc (NASDAQ:APLS) stock from “a Hold” to “a Buy”. The rating was released on February 05, 2024, according to finviz. The research report from Goldman has initiated the stock to Buy, with a price target set at $74. The stock was initiated by Mizuho, who disclosed in a research note on November 02, 2023, to Neutral and set the price objective to $42. In their research brief published October 06, 2023, JP Morgan analysts upgraded the Apellis Pharmaceuticals Inc stock from Neutral to Overweight with a price target of $81.

Historical Earnings Surprises and Revenue Forecasts

Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.73 during the last quarter as opposed to a consensus estimate of -$0.69, which indicates the company missed its estimate by -$0.04, which implies that the company surprised the market by -5.80%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2024) is -$0.54. This is an average of 11 analysts’ earnings, where the high earnings per share estimate is -$0.28 and the low earnings per share estimate is -$0.88. According to 13 analyst estimates, an average revenue estimate of $161.78M is projected for the current quarter with a high revenue estimate of $178.58M and a low estimate of $130.45M.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The latest trade, Performances and Moving Averages give us the following Picture

The firm’s stock price fluctuated 3.83% within the last five trades and -8.23% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 51.36% in the last 6 months and -6.61% was subtracted to its value over the previous 3 months. APLS stock is trading at a margin of -0.50%, -7.44% and 6.50% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

As of the close of trading, APLS deals in the Healthcare domain. The stock is trading -37.96 percent below its 52-week high and 196.42 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 35.7. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Apellis Pharmaceuticals Inc’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at -130.39 percent and the profit margin is -133.29 percent, and the company has reported a gross margin of 85.25 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $7.09 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 41.03. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 17.87 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 36.13, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 18.03 percent of Apellis Pharmaceuticals Inc shares are owned by insiders, and 91.92 percent are held by financial institutions. Dunlop A. Sinclair, the Director at Apellis Pharmaceuticals Inc (APLS) has sold 18,681 shares of firm on Mar 19 ’24 at a price of $57.18 against the total amount of $1.07 million. In another inside trade, DeLong Mark Jeffrey, Chief Business & Strat Officer of Apellis Pharmaceuticals Inc (NASDAQ:APLS) sold 9,913 shares of the firm on Mar 18 ’24 for a total worth of $0.56 million at a price of $56.90. An inside trade which took place on Mar 15 ’24, VP/Chief Accounting Officer of Apellis Pharmaceuticals Inc Chopas James George sold 184 shares of firm against total price of $10389.0 at the cost of $56.46 per share.

Most Popular

Related Posts